• Exploring the Role of Disease Burden, Treatment Effectiveness, and Administration Preference on Willingness of Patients With HAE to Change Long-Term Prophylaxis
    AAAAI | 2025 | Hereditary Angioedema (HAE)
  • HAE attack rates in pediatric patients 2 to <12 years of age with prophylactic berotralstat: results from interim analysis of APeX-P
    AAAAI | 2025 | Hereditary Angioedema (HAE)
  • Real-world attack rates before and after berotralstat initiation among patients with hereditary angioedema with C1-inhibitor deficiency (type I/II) stratified by monthly baseline HAE attack frequency
    AAAAI | 2025 | Hereditary Angioedema (HAE)
  • Real-world attack rates before and after berotralstat initiation among patients with hereditary angioedema without C1-inhibitor deficiency (HAE-nl-C1-INH) stratified by monthly baseline HAE attack frequency
    AAAAI | 2025 | Hereditary Angioedema (HAE)
  • Patient-reported impact of berotralstat as long-term prophylaxis on hereditary angioedema attack frequency and attack severity
    AAAAI | 2025 | Hereditary Angioedema (HAE)

Have questions about any of our medicines that are currently approved or in development, or would you like to request to be connected with an MSL?

Have questions about our company?